EVIDENCE PROFILE / PUBLISHED
Humanin
Humanin is a 24-amino-acid peptide attributed to the mitochondrial MT-RNR2 gene (the reviewed record notes possible nuclear encoding), distinct from the S14G mutant. The evidence reviewed is cell-culture work and one observational plasma study; no approved use or human administration study was found.
Evidence at a glance
- Human
- LimitedOne small observational study of endogenous plasma humanin (23 vs 58); no administration study.
- Animal/cell
- LimitedOne 2001 discovery paper, read at abstract level, reporting cell-culture experiments only.
- Approved medicine
- None foundOne Canadian active-ingredient register query with no product record; no approved label located.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. This concise profile was researched from primary and regulatory records; supplier listings were used only to find the name.
Identity
Humanin is described in the reviewed identity record as a 24-amino-acid peptide with the sequence MAPRGFSCLLLLTSEIDLPVKRRA, attributed to the mitochondrial MT-RNR2 gene, although the same record notes that the active peptide may instead be encoded by related nuclear genes. The record lists the S14G mutant separately, and notes that mitochondrial translation would give a shorter peptide lacking the last three C-terminal residues; neither is native humanin. A catalogue listing of the name proves nothing about the identity or composition of the material offered.
Biological mechanism or research interest
The reviewed identity record describes binding to BAX and IGFBP3 and ligand activity at the formyl peptide receptors FPR2 and FPR3, with JAK-STAT3 signalling through the humanin receptor complex. In the reviewed record these interactions are described mainly in relation to suppression of apoptosis and neuroprotection; the individual experiments behind them were not reviewed here.
Verified approved human uses
The Health Canada Drug Product Database active-ingredient API returned an empty result set for the ingredient name humanin, so no Canadian product record was found under that name in the sources reviewed. No other jurisdiction's register or label was reviewed. No approved human use was verified in the sources reviewed.
Investigational human evidence
A 2016 observational study measured endogenous plasma humanin by commercial ELISA in 23 people with impaired fasting glucose and 58 controls attending a diabetes complications screening clinic and reported a statistically significant between-group difference (P = 0.0001); the abstract describes this as a decrease in the impaired-fasting-glucose group, but the group means it reports are higher in that group than in controls, so the direction of the difference is left unresolved here. It administered nothing. A ClinicalTrials.gov query for humanin returned seven registered studies, none of them administering humanin or a humanin analogue; where humanin appears in those records it is a measured biomarker or outcome.
Popular claims versus demonstrated findings
Neuroprotection and other claims attached to this name rest, in the sources reviewed, on cell-culture work and curated mechanism summaries, or on associations between endogenous peptide levels and health status in observational human samples. No human administration study establishing safety or benefit was found in the sources reviewed, and findings reported for the S14G mutant do not transfer to native humanin.
Human versus animal or cell evidence
The 2001 discovery paper reports that humanin, identified by functional expression screening, prevented neuronal-cell death caused by several familial Alzheimer's disease genes and by amyloid-beta, but not death caused by Q79 or mutant SOD1. Those are cell-culture results and were read at abstract level only. No animal study was reviewed here, and the only human source located measured endogenous levels rather than giving the peptide.
Limitations and known risks
Human pharmacokinetics, route-specific safety, immunogenicity and impurity profiles were not characterized in the sources reviewed. The identity record also notes that the mechanisms of humanin production and secretion are unclear and that the active peptide may instead be encoded by related nuclear genes, so the name alone does not settle what a given preparation contains.
